Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: The kidney is a dose-limiting organ in [177Lu]-Dotatate PRRT (Lutate) and thus renal function is an important prescribing consideration for NET patients. The effect of baseline renal function on kidney absorbed dose is unclear.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Eslick E, Hayes A, Willowson K, Ryu H, Hennessy T,
Keywords: peptide receptor radionuclide therapy, Lutate, renal function, kidney absorbed dose,
Introduction: Lu-177 can be made with high specific activity and no other isotopes of lutetium present, referred to as “no carrier added” (nca) Lu-177. We have radiolabelled DOTA-conjugated peptide DOTA‐(Tyr3)‐octreotate (Auspep, Melb., AUS) with nca Lu-177 (“nca-LuTATE”) and used it in over 30 administrations in NETs patients.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Bailey D
Authors: Bailey D, Willowson K, Hennessy T, Schembri G, Snowdon G,
Keywords: lutetium, dosimetry, biodistribution, effective dose,
Introduction: Loco-regional lymph node and distant metastases are found very often in patients with MTC of less than 1 cm. There is not good MTC response to systemic chemotherapy or to external been radiotherapy. Radical thyroidectomy is the main method of therapy. Early diagnosis and correct N/M-staging are extremely important for the management of MTC. New hybrid SPECT-CT γ-cameras allow the fusion of anatomical and functional modalities. SPECT-CT is used in order to optimize somatostatin-receptor scintigraphic protocols.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Sergieva S
Authors: Sergieva S, Pandev R, Robev B, Fakirova A,
Keywords: MTC, somatostatin SPECT-CT image,
Introduction: Somatostatin analogues (SSA) represent one of the main therapeutic options in patients affected by functioning well-differentiated neuroendocrine tumors (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1).
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L,
Keywords: somatostatin analogues, MEN1, neuroendocrine tumors, pancreatic neuroendocrine tumor,
Introduction: In neuroendocrine tumors (NETs), the workup is often difficult not only to visualize but also to co-localize the lesions anatomically. Liver and bones are one of the most frequent sites of metastases in patients with endocrine tumors. The Tyr3-octreotate (TATE) somatostatin analogue differs from TOC in that the terminal threonine replaces threoninol. The terminal threonine results in a higher receptor binding (mainly subtype 2) and better internalisation, with the consequence that tumor uptake of the tracer is intense.
Conference: 7th Annual ENETSConcerence (2010)
Presenting Author: Szalus N
Authors: Szalus N, Pawlak D, Dziuk M, Koza M, Kaminski G,
Keywords: neuroendocrine tumors, SPECT/CT, PET/CT,